Woolsey Pharmaceuticals is at the forefront of developing innovative treatments for neurodegenerative diseases, with a primary focus on amyotrophic lateral sclerosis (ALS). Their lead product, BRAVYL (oral fasudil), is a Rho-kinase inhibitor that has shown promising results in preclinical studies and early human trials. The Phase 2a REAL study demonstrated that BRAVYL could potentially slow the progression of ALS, as evidenced by a statistically significant reduction in neurofilament light chain (NfL) levels, a biomarker associated with neuronal damage. The study also highlighted BRAVYL's favorable safety profile, with no participants withdrawing due to drug-related adverse events, suggesting its potential as a viable treatment option for ALS patients.

In addition to its primary indication for ALS, Woolsey Pharmaceuticals is actively exploring the broader applicability of BRAVYL for other neurodegenerative conditions, including Alzheimer’s Disease, Frontotemporal Dementia, and Parkinson’s Disease. The company has developed specialized formulations of BRAVYL to address challenges such as dysphagia, which is common among patients with neurodegenerative diseases. With a robust intellectual property portfolio, including multiple patents protecting the use of BRAVYL and its formulations, Woolsey is committed to advancing its pipeline to meet the significant unmet medical needs of patients affected by debilitating neurological disorders.

United States

Woolsey Pharmaceuticals is a biopharmaceutical company that provides therapeutics common diseases.

Woolsey Pharmaceuticals

Company Details